Search results for "Coagulation factor VII"

showing 2 items of 2 documents

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A

2019

Abstract Background and objective Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product stability under high and fluctuating temperatures is important, particularly for patients who reside in, or travel to, regions with high ambient temperatures, as they may remove their product from the refrigerator and return it, unused, multiple times. We evaluated the effect of variable temperature storage conditions, including up to 40 °C, on the stability of the recombinant FVIII product, turoctocog alfa. Methods Turoctocog alfa dry powder stability was assessed when moved between storage conditions of 5 °C (ambient humidity) and 40 °…

Hot TemperatureTime FactorsDrug StoragePharmacology toxicologyHemophilia A030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineAnimal scienceDrug StabilityAmbient humidityHumansPotencyRelative humidityIn patientOriginal Research Article030203 arthritis & rheumatologyPharmacologyFactor VIIIChemistrylcsh:RM1-950Turoctocog alfaCoagulation Factor VIII Room TemperatureStability Turoctocog-alfaRecombinant ProteinsCold TemperatureMolecular Weightlcsh:Therapeutics. PharmacologyDry powderOxidation-ReductionDrugs in R&D
researchProduct

Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report

2012

Transplantation in patients with congenital bleeding disorders is a challenge requiring an integrated approach of various specialists. Renal transplantation, the most frequent type of solid organ transplantation, is rarely performed in individuals with congenital hemorrhagic disorders. We performed a renal transplantation in a 53-year-old man with end-stage renal disease and congenital coagulation factor VII deficiency, a rare bleeding disorder with a peculiar clinical picture requiring replacement therapy in surgical interventions. Perioperative bleeding was successfully prevented by administration of recombinant activated factor VII. Treatment schedule, administration rate, and long-term …

Malemedicine.medical_specialtyDiseaseHemorrhagic disorderchemistry.chemical_compoundHumansMedicinekidney transplatation congenital bleeding disorders factor VII deficiency recombinant factor VII major surgerykidney transplantation inherited coagulation disorderCoagulation factor VIIKidney transplantationTransplantationFactor VIIbusiness.industryPerioperativeMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationchemistryTreatment ScheduleFeasibility StudiesKidney Failure ChronicSurgerybusiness
researchProduct